Akeso: We’re The Leaders In Bispecific Cancer Immunotherapies

 
• By Andrew McConaghie

The Chinese company is building on its success with ivonescimab and believes it can stay ahead of its rivals and develop into a global company.

The Shenzhen middle channel bridge in the Pearl river delta connects the cities of Shenzen and Zhongshan, where Akeso is headquartered. (Shutterstock)

More from Innovation

More from C-Suite Speaks